In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its shortage list. Here's what taking the drug of the list could mean for people taking tirzepatide or its compounded versions.

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of the wildly popular drug.

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to the drug makers, writing in bold that the agency "reminds compounders of the legal restrictions on making copies of FDA-approved drugs."

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and Zepbound.

We are now in the era of weight-loss drugs. Decisions on how these drugs will be used look likely to shape our future health and even what our society might look like. And, as researchers are finding,

The FDA said Eli Lilly’s weight-loss drugs were no longer in shortage on Oct. 2, preventing pharmacies from making cheaper versions. After an outcry, it’s reconsidering.

A new study suggests that medications like Ozempic could help reduce the risk of overdose and alcohol intoxication in people with substance use disorders.